Stay updated with breaking news from Harryr howard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A small Farmington biotech is looking to scale up after securing a patent for a novel pain treatment using a derivative of ketamine. MediSynergics, a company led by two former Pfizer drug researchers, operates out of a lab on the UConn Health campus as part of UConn’s Technology Incubation Program (TIP) program. The new patented compound shows promise as an alternative to opioid medications, said MediSynergics CEO Dennis M. Godek. “There’s a great need for new pain medications,” Godek said. “That’s the space that we’re working in. we’re trying to do our part.”
The new compound is also one of a group of derivatives discovered by the company that does not bind to the NMDA receptor in neurons, suggesting it may have fewer of the side effects that have limited ketamine’s use in treatment. The medication has worked well in mice and the company is seeking additional funding to expand testing, Godek said. ....